Genmab — Marts 2021
-
-
2020 was a big year for Genmab as we moved closer to achieving our vision of transforming cancer treatment and a strong pipeline of differentiated antibodies by 2025. Watch a few of our highlights... https://twitter.com/Genmab/status/1371476343079206912
-
Den bliver holdt i kort snor....
-
God morgen.
-
-
-
Aktier/åbning: Pandora i toppen og Carlsberg i bunden af positivt C25 https://www.proinvestor.com/investornyt/673155/aktier-abning-pandora-i-toppen-og-carlsberg-i-bunden-af-positivt-c25
-
Noget vi kender?: "Morphosys dykker med 13 pct. til 22,06 euro, efter at det tyske biotekselskab har skuffet med indtægtsprognosen for det nye regnskabsår." ... "Biotekselskabets prognose for investeringerne på 355-385 mio. euro er ifølge finanshuset også langt højere end ventet, og der fører også til et ventet negativ EBIT-resultat i år på 245-165 mio. euro, hvor konsensus lød på et tab på 178 mio. euro." Ritzau
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind